Comparable stake leader
Anna Protopapas
SEC ownership of Dicerna Pharmaceuticals Inc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001399529.
Disclosed value leader
Anna Protopapas
Comparable rows
0/2
Latest evidence
06 Jul 2021
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Anna Protopapas
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
06 Jul 2021
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001399529
- Issuer location
- Lexington, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Dicerna Pharmaceuticals Inc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Anna Protopapas
Disclosed value leader
Anna Protopapas
Comparable rows
0/2
Latest evidence
06 Jul 2021
3/4/5
Highest disclosed value: $127,487
2 rows are not safely comparable across share classes.
Quick read
Anna Protopapas has the largest disclosed position value at $127.5K.
0 of 2 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Anna Protopapas's linked filing trail.
Disclosed position value
Top 2
Anna Protopapas
$127.5K
Regina M. Paglia
$77.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-2 of 2 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Anna Protopapas |
3/4/5
Director
|
—
class O/S missing
|
$127,487
3,333 shares
|
— | 03 Jun 2021 |
| Regina M. Paglia |
3/4/5
Chief Human Resources Officer
|
—
mixed-class rows
|
$77,533
63,236 shares
mixed-class rows
|
— | 06 Jul 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 03 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Dicerna Pharmaceuticals Inc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
Anna Protopapas
Net 12M change
$0
Latest report
28 Dec 2021
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anna Protopapas | Director | $127,487 | Mixed | 03 Jun 2021 | ||
| Regina M. Paglia | Chief Human Resources Officer | $77,533 | Mixed | 06 Jul 2021 | ||
| Adam Koppel | Director | Mixed | 28 Dec 2021 | |||
| Marc D. Kozin | Director | Mixed | 28 Dec 2021 | |||
| Douglas Fambrough | Chief Executive Officer, Director | Mixed | 28 Dec 2021 | |||
| Cynthia Smith | Director | Mixed | 28 Dec 2021 | |||
| Stephen K. Doberstein | Director | Mixed | 28 Dec 2021 | |||
| Martin I. Freed | Director | Mixed | 28 Dec 2021 | |||
| Robert D. Ciappenelli | Chief Strategy Officer | Mixed | 28 Dec 2021 | |||
| Douglas W. Pagan | Chief Financial Officer | Mixed | 28 Dec 2021 | |||
| James B. Weissman | Chief Operating Officer & EVP | Mixed | 28 Dec 2021 | |||
| Stephen J. Hoffman | Director | Mixed | 28 Dec 2021 | |||
| J. Kevin Buchi | Director | Mixed | 28 Dec 2021 | |||
| Bob D. Brown | Chief Scientific Ofr., EVP R&D | Mixed | 28 Dec 2021 | |||
| Shreeram Aradhye | EVP & Chief Medical Officer | Mixed | 28 Dec 2021 | |||
| Ling Zeng | Chief Legal Officer & Sec'y | Mixed | 28 Dec 2021 | |||
| Patrick M. Gray | Director | Mixed | 28 Dec 2021 |
Recent insider transactions for Dicerna Pharmaceuticals Inc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.